UCLA scientists have made a significant breakthrough in the fight against triple-negative breast cancer with the discovery of a super-immunotherapy. This revolutionary treatment uses CAR-NKT cells to attack multiple tumor cell antigens, offering new hope for patients with this aggressive form of breast cancer. The CAR-NKT cells can be mass-produced from donated stem cells and stored for immediate use, making it a promising treatment option for those with triple-negative breast cancer.
Wiping Out Ovarian Cancer Protective Cells. Univ. of Chicago oncologist attack ovarian cancer by destroying the cells that protect it from therapy. #ovarian #cancer #immunotherapy #supportcells #nnmt
Researchers at the University of Chicago and the National Cancer Institute have made a groundbreaking discovery that may provide an effective therapy for ovarian cancer. By targeting Cancer Associated Fibroblasts (CAFs) and the tumor-induced enzyme NNMT, scientists have developed a powerful inhibitor compound that blocks the transformation of normal fibroblasts into CAFs, effectively halting tumor growth. This innovative approach may hold the key to improving survival rates and quality of life for ovarian cancer patients.
0 likes, 0 comments - drhowardsmithreports on March 11, 2025: "Improving Ovarian Cancer Immunotherapy Immunotherapy has been a resounding success for melanoma skin cancer and small cell lung cancer. Not so for ovarian cancer. Cancer immunologists at the University of Virginia have now discovered what underlies this failure. Their research discovered that flagellin protein from gut bacteria blocks the effectiveness of the checkpoint inhibitors that power most current immunotherapy. This bacterial flagellin inhibits immune cell communication helping tumors flourish rather than die. Using a mouse model and blocking flagellin action restored immunotherapeutic effectiveness with 80% of treated animals enjoying long-term tumor control. If this approach is effective for human ovarian cancer patients, coupling flagellin blocking with checkpoint immunotherapy may be a winning therapeutic strategy …..someday soon. https://newsroom.uvahealth.com/2025/02/11/ovarian-cancer-discovery-could-turn-ailed-treatment-into-lifesaver/ https://aacrjournals.org/cancerimmunolres/article-abstract/doi/10.1158/2326-6066.CIR-24-0513/751676/TLR5-signaling-causes-dendritic-cell-dysfunction?redirectedFrom=fulltext #immunotherapy #checkpointinhibitor #ovarian #cancer #biome #flagellin".
This joint guideline from ESGAR, ESUR, PSOGI, and EANM provides expert consensus on diagnostic imaging for peritoneal metastases in #ovarian and #colorectal cancers, covering imaging modalities, operability assessment, treatment response monitoring, and follow-up for improved patient care. (Vincent Vandecaveye et al.)
Objectives Diagnostic imaging of peritoneal metastases in ovarian and colorectal cancer remains pivotal in selecting the most appropriate treatment and balancing clinical benefit with treatment-related morbidity and mortality. To address the challenges related to diagnostic imaging and detecting and reporting peritoneal metastatic spread, a joint guideline was created by the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), European Society of Urogenital Radiology (ESUR), Peritoneal Surface Oncology Group International (PSOGI), and European Association of Nuclear Medicine (EANM). Methods A targeted literature search was performed and consensus recommendations were proposed using Delphi questionnaires and a five-point Likert scale. Results A total of three Delphi rounds were performed. Consensus was reached on the position of diagnostic imaging for assessment of operability, treatment response monitoring, and follow-up of peritoneal metastases, optimal imaging modality and their technical imaging requirements depending on the indication and how to optimise communication of imaging results by the report and multidisciplinary board discussion. The complete list of recommendations is provided. Conclusion These expert consensus statements aim to guide appropriate indications, acquisition, interpretation, and reporting of imaging for operability assessment, treatment response monitoring, and follow-up of peritoneal metastases in ovarian and colorectal cancer patients. Key Points Question Staging peritoneal metastases (PM) helps to guide clinical decision-making for colorectal and ovarian cancer patients. How can we optimise the use of imaging techniques to assess PM? Findings Imaging plays a crucial role in the detection, operability assessment, treatment response monitoring, and follow-up of peritoneal metastases in colorectal and ovarian cancer patients. Clinical relevance These expert consensus statements aim to guide appropriate indication, acquisition, interpretation, and reporting of imaging for operability assessment, treatment response monitoring, and follow-up of peritoneal metastases in ovarian and colorectal cancer patients.
It checks the 12 most common forms of the disease: #lung, #breast, #prostate, #pancreatic, #colorectal, #ovarian, #liver, #brain, #oesophageal, #bladder, #bone and soft tissue #sarcoma, and #gastric.
Scientists at Southampton University are understood to have used clinical information from 20,000 cancer patients to develop the screening.
The next stage involves improving the efficacy of the artificial intelligence involved, which analyses the test samples and biomarkers”
(2/2)
Scientific Frontline
Wordmark
Howard Smith MD, AM
PLOS Biology
European Radiology
Auscandoc